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Abstract
Background: Awareness of a patient’s anxiety, depression, and quality of life (QOL) in those
with metastatic uveal melanoma (MUM) can influence care that meets patients’ bio-psychosocial-spiritual needs.
Objectives: To measure the level of anxiety, depression, and QOL in patients with MUM and
explore differences by gender, age range, time to metastatic disease, and duration of illness since
metastasis.
Methods: We used a descriptive-comparative survey design. Over three months, a convenience
sample of 70 patients with MUM aged ≥ 18 years, treated at a Mid-Atlantic hospital were invited
to complete a combined survey of the Hospital Anxiety and Depression Scale and the World
Health Organization Quality of Life-BREF.
Results: There were 65 respondents (93% response rate). 30.8% (n=20) had at least borderline
anxiety, 13.8% (n=9) had at least borderline depression, and 32.3% (n=21) had a decrease in
global QOL. Patients 18 to ≤ 60 years had higher anxiety scores (p=0.003) and lower QOL
scores in environmental health (p=0.006). Those with a shorter duration of illness since
metastasis had higher anxiety scores (p=0.01) and higher QOL scores in physical health
(p=0.05). No differences were found by gender or time to metastatic disease.
Conclusions: Up to 30% of participants had at least borderline anxiety and a decreased global
QOL while up to 10% had at least borderline depression. These findings support the integration
of bio-psycho-social-spiritual practices in the care of patients with MUM.
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Background
The comprehensive health care approach encompasses services that are pertinent to the
well-being of individuals. It utilizes integrated interprofessional teams to address physical,
social, and psychological needs of patients throughout the continuum of care (Bakitas, Lyons,
Hegel, & Ahles, 2013). Yet, challenges remain in addressing psychosocial needs of patients,
especially those who are faced with life threatening illnesses. One particularly vulnerable group
is that of patients diagnosed with metastatic uveal melanoma (MUM), a rare and incurable
malignancy that originates as a melanoma of the uveal tract without known risk factors
(American Cancer Society [ACS], 2014).
Epidemiology of Metastatic Uveal Melanoma
This tumor is prevalent among people of northern European descent with blue eyes, fair
skin, and those with outdoor occupations (Eschelman, Gonsalves, & Sato, 2013). However,
unlike skin melanoma, there is no convincing evidence that uveal melanoma is related to
ultraviolet exposure (Eschelman et al., 2013). In the United States, approximately 2,000 adults
are diagnosed with ocular melanoma annually (Ocular Melanoma Foundation, 2016). The
prognosis of uveal melanoma remains poor with a 5-year relative survival rate of 75% if cancer
is confined to the uveal tract compared to only 15% in case of metastasis despite advanced
treatment technologies (ACS, 2014).
Treatment of Metastatic Uveal Melanoma
The most common treatment of primary uveal melanoma includes eye radiation for small
tumors and eye enucleation for complicated tumors (Eschelman et al., 2013; Shields & Shields,
2004). Despite intraocular melanoma therapy, about 50% of patients with primary uveal
melanoma develop distant metastasis, the liver is affected in about 90%, lung in 29%, and bone
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in 17% (Buder, Gesierich, Goebeler, & Gelbrich, 2013; Eschelman, et al., 2013; Spagnolo,
Caltabiano, & Queirolo, 2012). When hepatic metastasis occurs, locoregional therapy to the liver
is recommended to stabilize tumor growth and halt the progression of disease (Eschelman et al.,
2013). Systemic treatment approaches are suggested when extrahepatic metastasis occurs.
The treatment of metastatic uveal melanoma is complex and requires highly specialized
care in referral practices of MUM. A large teaching hospital in the Mid-Atlantic offers 5 leading
modalities of liver directed treatment for MUM, namely immunoembolization, selective internal
radiation therapy, transarterial chemoembolization, drug-eluting beads (Eschelman et al., 2013),
and chemosaturation with percutaneous hepatic perfusion. Also, this referral practice of MUM is
one of the few institutions worldwide that offer a systemic clinical trial of immunocore gp100, an
orphan drug targeting T-cell receptors for the treatment of MUM (Immunocore Limited, 2016).
Every week, about 15 patients with MUM come to this hospital seeking liver directed therapy or
systemic immunotherapies. In 2016, approximately 640 liver-directed treatment procedures were
performed for patients with MUM in this institution. While the medical treatment of these
patients continues to evolve with new technologies, identification and treatment of co-morbid
anxiety, depression, and other psychosocial problems needs attention.
Problem Statement
Patients diagnosed with MUM undergo multiple tests and treatments from the initial
diagnosis of uveal melanoma to metastasis. These events may lead to psychological distress and
life-changing challenges, which should require unique assessment and intervention throughout
the continuum of care, survivorship, and end of life. In this organization, psychosocial needs of
patients with MUM have not been routinely assessed and addressed in everyday clinical practice.
Yet, if you are caring for the whole patient, these issues need to be incorporated in providing

ANXIETY-DEPRESSION-QUALITY OF LIFE

5

holistic care (Dossey & Keegan, 2013). Hence, identifying and isolating these psychosocial
needs could lead to the development and implementation of strategies that put forward
psychosocial care in an attempt to ameliorate the quality of life of these patients (Dossey &
Keegan, 2013). Considering the number of patients with MUM who seek care within this
organization, we believed that investigation of their psychosocial health status was warranted.
Purpose
The purpose of this study was to assess the levels of anxiety, depression, and quality of
life of patients with MUM. The long term purpose of this research is to design an
interprofessional translational action plan geared toward addressing bio-psycho-social-spiritual
needs and ultimately, improving quality of life and holistic well-being of patients with MUM.
Objectives
The primary objective of this pilot study was to measure the level of anxiety, depression,
and quality of life in patients with MUM. The secondary objective was to explore potential
differences in the levels of anxiety, depression, and quality of life by gender, age range, time
elapsed between the initial diagnosis of uveal melanoma and metastasis, and duration of illness
since the diagnosis of metastasis.
Research Questions
1. In patients with MUM aged 18 and older, what is the level of anxiety, depression, and
perceived quality of life?
2. How many patients with MUM had at least borderline anxiety (scores ≥8), at least
borderline depression (scores ≥8), and a decrease in global QOL (scores <7)?
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Hypotheses
This pilot study was a hypothesis-generating study intended to produce preliminary data
for a potential larger and powered study that would test the following research hypotheses:
In patients with MUM:
1. There is a difference between gender and:


anxiety scores



depression scores



QOL scores

2. There is a difference between age categories and:


anxiety scores



depression scores



QOL scores

3. There is a difference between the time elapsed between the initial diagnosis of uveal
melanoma and the diagnosis of metastasis and:


anxiety scores



depression scores



QOL scores

4. There is a difference between the duration of illness since metastasis and:


anxiety scores



depression scores



QOL scores
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Significance
The chase for the mysteries of uveal melanoma persists. Up until now, research studies
on uveal melanoma have long focused on the epidemiology of this malignancy, how to halt its
progression, and how to prolong survival (Eschelman et al., 2013; Field & Harbour, 2014;
Orloff, Sato, Valsecchi, & Sato, 2015). Dr. Carol Shields, a renowned ophthalmologist and
ocular oncology specialist has phrased this search as a “continuing hunt for the secrets of uveal
melanoma” (Shields, 2008). Yet, only a few studies have tackled the psychosocial aspect of
uveal melanoma from the patient's perspective (Reimer et al., 2006).
It is undisputable that providing patient-and family-centered care that meets patients’ biopsycho-social-spiritual needs improves patients’ satisfaction and sets healthcare organizations
apart (Institute for Patient- and Family-Centered Care, n.d.). Likewise, healthcare providers who
are cognizant of their patients’ overall health status hold promise for preserving the quality of
healthcare for their patients, families, and communities (Institute on cancer patients and their
families (McFarland & Holland, 2016).
The ideology of patient-and family-centered care remains one of the fundamental aims
for improving the health care quality of patients with MUM. This study is significant in the
cancer ward because with the rarity of uveal melanoma, and its pattern of disease progression
and aggressiveness, the quality of a patient's life can be greatly affected by bouts of anxiety,
depression, and feeling of low perceived emotional support. Our study examined the levels of
these psychosocial challenges among patients with MUM, which had not been previously
reviewed. Tackling these serious concerns has the potential to improve quality of life.
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Literature Review
Psychosocial Distress in Cancer Patients
Patients diagnosed with cancer are likely to present symptoms associated with
psychosocial disturbances, including anxiety, depression, and decreased quality of life (Die,
2012; Mitchell et al., 2011; Schuermeyer et al., 2016). A meta-analysis of 94 interview-based
studies of 14078 patients with cancer found depression in 20.7%, depression or adjustment
disorder in 31.6%, and anxiety or any mood disorder in 38.2% (Mitchell et al., 2011).
Risk Factors for Psychosocial Stress
Some types of cancer are linked to greater rates of anxiety and depression than others
(Schuermeyer et al., 2016). There are specific risk factors that have been identified in cancer in
general that may help to recognize those at greater risk. Some of these factors include gender,
age, cancer type, and prognosis.
Studies have suggested that the level of psychiatric disturbances differ by gender (Kessler
et al., 1994; McLean, Asnaani, Litz, & Hofmann, 2011). Using 20,013 adults from the
Collaborative Psychiatric Epidemiology Studies (CPES) data, McLean et al. (2011) showed that
women are more likely than men to develop anxiety disorders throughout the lifetime with a
male: female prevalence ratio of 1:1.7.
Another prospective longitudinal study was conducted among 500 cancer patients with an
average age of 73.1 to investigate the association between age, anxiety, and depression in older
adults diagnosed with cancer (Weiss et al., 2015). In this study, clinically significant anxiety was
reported in 20.9% and clinically significant depression was reported in 12.6% (Weiss et al.,
2015). Additionally, it was noted that with increasing age, anxiety decreased while depression
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remained constant (Weiss et al., 2015). Hence, it is warranted to assess and address the
psychological sequelae of cancer across the age spectrum.
A synthesis of the literature reviewed showed that psychological distress in cancer
patients depends on the cancer type and varies overtime (Reimer et al., 2006; Schuermeyer et al.,
2016; Turnbull et al., 2012). The dynamic life altering experiences suggests the necessity to
examine bio-psycho-social-spiritual needs of cancer patients in daily clinical practice in light of
patient-centered care approach.
Psychosocial Distress in Patients with Metastatic Uveal Melanoma
The poor prognosis of uveal melanoma despite advanced treatment multimodalities
(ACS, 2014; Eschelman, et al., 2013; Singh, Turell, & Topham, 2011) makes it likely for uveal
melanoma patients to incur psychosocial distress and life-changing challenges that may impact
the quality of life throughout the continuum of care from the initial diagnosis of uveal melanoma
to metastasis, survivorship, and end of life.
Prior studies have already begun to show that the diagnosis of uveal melanoma and its
progression impair the holistic well-being of individuals and their families beyond the physical
appearance and the clinical presentation of the patient. In a prospective study among 54 patients
diagnosed with uveal melanoma, Reimer and his colleagues (2006) found that the diagnosis of
choroidal melanoma impaired quality of life, which was further compromised among patients
who underwent eye radiotherapy. Data were collected before eye radiotherapy and at 3 months
after radioactive eye therapy. They found that global QOL of ocular melanoma patients
deteriorated after radioactive therapy likely due to the increase in patients with visual damage
from 21 preoperatively to 34 postoperatively (Reimer et al., 2006).
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As noted above, factors influencing psychosocial distress and affect quality of life are
complex and change throughout the continuum of care. In a prospective longitudinal study of 96
patients with uveal melanoma at an institutional referral practice, Schuermeyer et al. (2016)
revealed that patients who underwent prognostication for their primary uveal melanoma had the
highest level of decision regret at 3 months following prognostic genetic testing. However, this
decision regret decreased at 12 months following this testing. Nevertheless, little is known
regarding the variation in the level of psychosocial needs of patients with MUM when metastasis
occurs and throughout the continuum of care.
In this study, a more tailored approach to understanding the needs of patients with MUM
was evaluated taking into consideration the demographic status, the time elapsed between the
initial diagnosis of uveal melanoma and metastasis, and the duration of illness since the
diagnosis of metastasis in order to provide more effective psychosocial support.
Theoretical Foundation
In examining a theoretical perspective that supports the value of exploring the level of
anxiety, depression, and quality of life in patients with MUM as well as tailoring a psychosocial
management plan to match the needs of the particular patient to improve quality of life, the
psychosocial oncology framework provides a useful model. This theoretical framework
conceptualizes what type of psychosocial help cancer patients and their families might require
and proposes service delivery approach at both the provider and system levels (Turnbull et al.,
2012). Basically, this framework echoes the advantage of regularly assessing the needs of people
affected by cancer, implementing routine supportive care screening, identifying supportive care
needs, providing referral and linkages to suitable services, and ameliorating the capacity of the
health system to address and provide comprehensive care (Turnbull et al., 2012).
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The framework for psychosocial oncology care provides a concrete set of 31 actionable
recommendations grouped into 8 major domains upon which the cancer care team may
collectively utilize to review existing services, identify gaps, and revise services to ensure quality
psychosocial care and services based on psychosocial distress experienced by cancer patients and
their families (Turnbull et al., 2012). These domains aim to raise awareness and understanding of
psychosocial care (Domain A), provide standard of care for screening and management of
psychosocial health care needs (Domain B), delineate expectation of health care providers in
terms of education, training, and communication of psychosocial issues (Domain C), define
patient and family education (Domain D), explain quality oversight and monitor progress of
psychosocial services (Domain E), enlighten workforce competencies for cancer services
(Domain F), standardize transdisciplinary classification for psychosocial health services (Domain
G), and promote psychosocial research (Domain H) (Turnbull et al., 2012).
The principles of psychosocial and supportive care needs have been recommended in the
care of patients with the diagnosis of cancer (Fitch, 2008; State Government Victoria, n.d.;
Turnbull et al., 2012; Yun et al., 2010). Similarly, in the care of patients with MUM, it is
essential to plan care based on what type of needs and services these patients and their families
might necessitate in the domains of physical, psychological, social, information, and spiritual
across the cancer trajectory from initial diagnosis of metastatic uveal melanoma through
bereavement. Henceforth, in light of the interprofessional care approach extended to patients
with MUM and their families, the principles of supportive care needs may be applied to establish
and deliver psychosocial care in an attempt to improve the quality of life of these patients.
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Identifying and Defining Variables
The psychosocial disturbances among metastatic uveal melanoma patients may echo the
dependent variables of the level of anxiety, level of depression, and the perceived quality of life.
These dependent variables may be affected by independent clinical variables of the time elapsed
between the initial diagnosis of uveal melanoma and the diagnosis of metastasis, and the duration
of illness since the diagnosis of metastasis. In addition, independent demographic variables of
gender and age range may have an impact on bio-psycho-social-spiritual health of these patients.
Other demographic variables include race/ethnicity, level of education, employment status,
marital status, parental status, and being a parent of a child younger than 18 years.
The variables with theoretical and operational definitions are displayed in Table 1. The
causal interaction of variables within this study is depicted in Appendix A.
Methods
Research Design
A descriptive-comparative survey design was used in this research study. This survey,
collected at one point in time, addressed the proposed research question on the level of anxiety,
level of depression, and perceived quality of life in patients with MUM aged 18 years and older.
Also, it addressed the proposed research question on how many patients with MUM had at least
borderline anxiety (scores ≥8), at least borderline depression (scores ≥8), and a decrease in
global QOL (scores <7). Moreover, this design was appropriate to explore whether there is a
difference in level of anxiety, level of depression, and perceived quality of life in patients with
MUM based on their gender, age categories, the time elapsed between the initial diagnosis of
uveal melanoma and metastasis, and the duration of illness since metastasis.
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Study Sample
The target population of this study was all patients with MUM receiving care at a MidAtlantic referral practice of MUM. Other inclusion criteria for this pilot study included patients
with MUM aged 18 years and older, residing in the United States regardless of their gender, race
or ethnic backgrounds, religion, belief, education, socioeconomic status, or state of residence. As
of May 15, 2017, there were 136 patients with MUM established in this institution. They were
comprised of 60 male and 76 female. Based on their age group, 2 were between the age of 18
and 34 years, 81 were between the age of 35 and 60 years, and 53 were over 60 years. These
patients were notified in writing about the study.
Sample Size
In this convenience sampling, we approached only established patients with MUM who
presented at this Mid-Atlantic institution for treatment or clinical follow-ups during the threemonth study period of September 1 - December 1, 2017. Patients who could not read the surveys
were included and voluntarily completed the survey with the assistance of the investigators who
read questions to them. Patients who did not speak English were excluded from this study. There
were 70 eligible patients with MUM who met the above criteria (Appendix B).
Power Analysis
This pilot study was intended to provide preliminary data for a potential larger and
powered study which would examine whether there is a relationship between the endpoints (level
of anxiety, level of depression, and perceived quality of life) and demographic and socioeconomic variables as well as the time elapsed between the initial diagnosis of uveal melanoma
and the diagnosis of metastasis and the duration of illness since the diagnosis of metastasis.
Given the poor prognosis of metastatic uveal melanoma and the limited survival rate (ACS,
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2014), we expected 30-40% of patients with MUM to have a score of 8 or more on the Hospital
Anxiety and Depression Scale (HADS) reflecting at least borderline anxiety or depression. If true
in the population, then a sample of 50 patients would provide 95% Clopper-Pearson exact
confidence intervals for the estimated prevalence of anxiety of (0.18, 0.45) and (0.26, 0.55), for
prevalence estimates 30% and 40%, respectively (Appendix B).
Recruitment of Subjects
Following two institutional review board (IRB) approvals, the principal investigator
mailed the IRB approved invitation flyer and subject recruitment letter to all patients with MUM
receiving care at a Mid-Atlantic referral practice of MUM. Both the flyer and the recruitment
letter specified the ages for eligibility, stipulated the anonymity of the participants, stated the
purpose of the study, included the benefits of participation, specified the contact person’s name,
and identified the location of the study. Thereafter, the investigators met with every patient with
MUM who presented at the multidisciplinary melanoma clinic, outpatient infusion center, or
inpatient care area during the allotted study period of 3 months to ensure that the patient had
received the recruitment letter, answer questions about the study, and determine whether the
patient wanted to participate.
Setting
The setting for this study was a large teaching hospital in the Mid-Atlantic, a referral
practice of MUM.
Instruments and Measurement
The demographic data sheet (Appendix C), the HADS (Appendix D), and the World
Health Organization Quality of Life (WHOQOL)-BREF questionnaire (Appendix E) were used
to collect data in this study. The demographic data sheet included questions on the independent
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variables, namely, gender, age range, the time elapsed between the initial diagnosis of uveal
melanoma and metastasis, and the duration of illness since the diagnosis of metastasis. Other
demographic data collected were race, ethnicity, highest level of education completed,
employment status, marital status, parental status, and being a parent of a child < 18 years.
Participants were not required to provide their names, date and month of birth, addresses, phone
numbers, or any other identifiable information on the survey. Permission to use HADS and
WHOQOL-BREF questionnaire were granted by GL Education Group Limited and World
Health Organization, respectively.
During the period of September 1 - December 1, 2017, a one data collection point using
paper surveys of the HADS (Appendix D) and the WHOQOL-BREF (Appendix E) were
distributed to patients with MUM who had voluntarily agreed to participate in this study.
Surveys were completed and collected on the same day at the multidisciplinary melanoma clinic,
outpatient infusion center, or inpatient care area. The principal investigator or the co-investigator
was present on site to assist with the completion of the survey as needed. At the end of the
survey, a handmade thank you gift from Rwanda, the principal investigator’s native country, was
given to participants (Appendix F). To our knowledge, there was no previous study that has used
HADS or WHOQOL-BREF in patients with MUM.
Hospital Anxiety and Depression Scale
The hospital anxiety and depression scale (HADS) is a frequently used psychological
screening instrument that has been applied in clinical and research settings. It gives clinically
meaningful screening of anxiety and depression in both individual patients with illness and in the
general population (GL Education Group, n.d.). In a review of literature of the validity of the
HADS, Bjelland, Dahl, Haug, and Neckelmann (2002) have identified 747 articles in Medline,
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ISI, and PsycINFO that have referred to HADS. HADS encompasses seven questions for anxiety
and seven questions for depression that can be completed in about 2 to 5 minutes (Stern, 2014;
Appendix D). It was deemed to be a reliable and valid instrument for screening anxiety and
depression in individuals (Bjelland et al., 2002; Stern, 2014). Scores for each subscale range
from 0 to 21 and are 4-point Likert scale with a range of 0-3. The level of anxiety or depression
score is estimated to be normal (0-7), borderline abnormal (score 8-10), and abnormal (score 1121) (Bjelland, Dahl, Haug, & Neckelmann, 2002; Zigmond & Snaith, 1983). A score of 8 or
more for anxiety has a specificity of 0.78 and a sensitivity of 0.9 whereas the same score for
depression has a specificity of 0.79 and a sensitivity of 0.83 (Bjelland et al., 2002; Stern, 2014).
Thus, a score of 8 or more for anxiety or depression should alert the clinician for a thorough
psychosocial and mental health evaluation.
World Health Organization Quality of Life-BREF
The World Health Organization Quality of Life (WHOQOL)-BREF is a 26-item version
of the WHOQOL-100 assessment (WHO, 2004; Skevington, Lotfy, O'Connell, & WHOQOL
Group, 2004). It was reported that WHOQOL-BREF could be self-administered in UK by well
people, in less than 5 min (Skevington et al., 2004). The WHOQOL-BREF consists of seven
items in the domain of physical health (QOL domain 1) which includes mobility, daily activities,
functional capacity, energy, pain, and sleep; six items in psychological health (QOL domain 2)
which is pertinent to self-image, negative thoughts, positive attitudes, self-esteem, mentality,
learning ability, memory concentration, religion, and the mental status; three items in social
relationships (QOL domain 3) which is related to personal relationships, social support, and sex
life; eight items in environmental health (QOL domain 4) which includes issues related to
financial resources, safety, health and social services, living physical environment, opportunities
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to acquire new skills and knowledge, recreation, general environment (noise, air pollution, etc.),
and transportation; as well as two items in global QOL and general health (WHO, 2004;
Appendix I). Each item is Likert scaled from 1 to 5 on a response scale which correlates to a
five-point on an ordinal scale. Scores range from 7 to 35 in domain 1, from 6 to 30 in domain 2,
from 3 to 15 in domain 3, from 8 to 40 in domain 4, and from 2 to 10 in global QOL (Skevington
et al., 2004; WHO, 2004). A higher score in each domain corresponds to a better QOL (WHO,
2004).
The WHOQOL-BREF has been tested in numerous populations worldwide and is
considered to be a rigorous cross-culturally valid and reliable assessment of QOL (Skevington et
al., 2004). A large study of 11,830 individuals from 24 countries responded to the WHOQOLBREF questionnaire. Among them, 17% had a diagnosis of cancer, 11% had diabetes, 11% had
depression, 11% had cardiovascular diseases and hypertension, and 4% had musculoskeletal
problems (Skevington et al., 2004). In this study, a measure of the internal consistency showed
Cronbach’s alpha of 0.82 for domain 1 of physical health, 0.81 for domain 2 of psychological
health, 0.68 for domain 3 of social relationships, and 0.80 for domain 4 of environmental health
(Skevington et al., 2004). To establish discriminant validity, mean scores for facets and domains
of physical, psychological, level of independence, social relations, environment, and spirit were
calculated for 4644 ill and 3187 well sample populations (WHO, 1998). The WHOQOL-100
showed scores ranging from 5% to 18.5% lower for ill participants than for well participants on
all four domains (WHO, 1998).
Data Collection Procedure
Data collection began following both institutional review board approval. The data
collection was performed by either the principal investigator or the co-investigator from
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September 1, 2017 through December 1, 2017. The paper-pencil survey was distributed daily to
patients with MUM who presented at the Mid-Atlantic referral practice of MUM for their
treatment or clinic appointment during the survey period. The investigator collected the survey in
a sealable envelope on the same day immediately after completion. To prevent duplicates in the
survey, respondents were asked to complete the survey only once. Approximately 15 minutes
were expected to complete both the HADS and WHOQOL-BREF questionnaires (Skevington et
al., 2004; Stern, 2014). There was a handmade ornament from Rwanda given to participants after
taking the survey (Appendix F). The completed surveys were placed in the principal
investigator’s locked desk. The key for the locked box was kept in the researcher’s office.
To ensure fidelity to study protocol as well as validity and reliability of data collection
plan, surveys were organized and available to all patients with MUM based on their clinical
appointments during the data collection period. This process facilitated in delivering the survey
as intended and could be replicated to other patients with MUM who receive care in other
institutions. In addition, all variables were clearly demarcated to facilitate data abstraction
(Borrelli, 2011). The principal investigator entered all data on a password protected
Microsoft Excel worksheet (Appendix G). Also, one of this project’s co-advisors checked 10%
of the sample for accuracy of data entry. Data codes are defined in Appendix H.
Data Analysis Plan
In our study, a descriptive analysis was conducted for demographic and clinical
characteristics of the sample. Also, descriptive statistics were used to analyze data collected,
including the frequency and percent for categorical data as well as the mean and standard
deviation for interval data. Once recoded, data from Excel were downloaded directly into IBM
SPSS Statistics 24 for data storage, analysis, and reporting. With this pilot study, we examined
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whether there were potential differences in the level of anxiety, level of depression, and QOL in
patients with MUM based on gender, age categories, and the time elapsed between the initial
diagnosis of uveal melanoma and metastasis using an independent t-test. Moreover, we tested
whether there were potential differences in the level of anxiety, level of depression, and QOL in
patients with MUM based on the duration of illness since the diagnosis of metastasis using
analysis of variance (ANOVA) and p-value.
The independent t-test was used to analyze two averages means on the same dependent
variable (Statistics How To, 2017). ANOVA was used to analyze the variation in a scale-level
dependent variable having more than 2 categories (Statistics Solutions, 2013). The p-value was
calculated to illustrate the probability of observing the data if the null hypothesis was true and
helped support or reject the null hypothesis (Statistics How To, 2017). Cronbach’s Alpha was
used to measure the reliability of dependent variables.
By assuming that there was a difference in level of anxiety, level of depression, and QOL
in patients with MUM based on gender, the independent t-test was used to assess if the
dependent variables of anxiety score, depression score, and QOL scores were related to the
independent variable of gender (2 groups). By positing that there was a difference in level of
anxiety, level of depression, and QOL in patients with MUM based on two age categories of 18
years to ≤60 years and above 60 years, the independent t-test was used to assess if the dependent
variables of anxiety score, depression score, and QOL scores were related to the independent
variable of age groups (2 groups). By assuming that there was a difference in level of anxiety,
level of depression, and QOL in patients with MUM based on the time elapsed between the
initial diagnosis of uveal melanoma and the diagnosis of metastasis, the independent t-test was
used to evaluate if the dependent variables of anxiety score, depression score, and QOL scores
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were related to the independent variable of time elapsed between the initial diagnosis of uveal
melanoma and the diagnosis of metastasis (2 groups). By postulating that there was a difference
in level of anxiety, level of depression, and QOL in patients with MUM based on the duration of
illness since the diagnosis of metastasis, ANOVA was used to evaluate if the dependent variables
of anxiety score, depression score, and QOL scores were related to the independent variable of
duration of illness since the diagnosis of metastasis (3 groups).
In addition, we conjectured that there was a difference among each domain of quality of
life (physical health, psychological health, social relationships, and environmental health) based
on gender, age range, time elapsed between the initial diagnosis of uveal melanoma and
metastasis, and duration of illness since the diagnosis of metastasis. In the same way, the
independent t-test was used to assess if each domain of QOL and the global health were related
to the independent variable of gender, age categories, and the time elapsed between the initial
diagnosis of uveal melanoma and the diagnosis of metastasis. ANOVA was used to evaluate if
each domain of QOL was related to the independent variable of the duration of illness since the
diagnosis of metastasis (3 groups).
Steps for checking and cleaning data and computing domain scores for the WHOQOLBREF are delineated in Appendix I.
Ethical Considerations
This oncology-related study on patients with MUM was approved by the Melanoma
Multidisciplinary Disease Group (MDG), approved by the Protocol Facilitation Committee,
approved by the Protocol Review Committee (PRC), acknowledged by the Office of Nursing
Research, and exempted by the IRB. Study participation was voluntary. The data collection
spreadsheet was password protected.
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Results
Reliability testing
In this study, a measure of the internal reliability of the hospital anxiety and depression
scale showed Cronbach’s alpha of 0.81 for anxiety and Cronbach’s alpha of 0.83 for depression.
A measure of the internal reliability of the World Health Organization Quality of Life-BREF
questionnaire showed Cronbach’s alpha of 0.84 for domain 1 of physical health, 0.89 for domain
2 of psychological health, 0.90 for domain 4 of environmental health, and 0.56 for global QOL.
It also showed very low internal consistency between the 3 items in domain 3 of social
relationships (Cronbach’s alpha of 0.004) due to item 21 asking “How satisfied are you with
your sex life?” If this item was deleted, Cronbach’s Alpha would have been 0.68 for domain 3.
Demographic and Clinical Characteristic of the Sample
There were 136 potentially eligible patients with MUM. Only 70 patients with MUM
presented to the Mid-Atlantic referral practice of MUM during the allotted survey period of
September 1-December 1, 2017 and were offered to complete the survey. Among them, 65
completed the survey with a response rate of 93%. Of the total sample, the majority were female
(56.9 %, n=37), older than 60 years (55.4%, n=36), white (98.5%, n=64), had a college education
or above (78.5%, n=51), non-employed (56.9%, n=37), married (80%, n=52), parents of children
(83.1%, n=54), but did not have a child less than 18 years (73.8%, n=48; Table 2).
The time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of
metastasis was <1 year in 10.8% (n=7), 1 year to <5 years in 61.5% (n=40), <5 years in 72.3%
(n=47), and ≥ 5 years in 27.7% (n=18). The duration of illness since the diagnosis of metastasis
was <1 year in 29.2% (n=19), 1 year to <5 years in 55.4% (n=36), and ≥ 5 years in 15.4%
(n=10).
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Research Questions Results
In our total sample, (Table 3), the mean anxiety score was 6.05 ± 3.64, the mean
depression score was 3.48 ± 3.27, the mean domain 1 score for physical health was 27.28 ± 5.38,
the mean domain 2 score for psychological health was 23.52 ± 4.59, the mean domain 3 score for
social relationships was 11.71 ± 2.35, the mean domain 4 score for environmental health was
34.40 ± 5.13, and the mean score for global QOL was 7.22 ± 1.57. In addition, among
respondents with MUM, 30.8% (n=20) had anxiety scores ≥8, 13.8% (n=9) had depression
scores ≥ 8, and 32.3% (n=21) had global QOL scores <7 (Table 2) indicating at least borderline
anxiety, at least borderline depression, and decreased QOL scores.
Hypotheses Testing Results
Hypothesis 1, which was tested to calculate differences in anxiety, depression, and QOL
scores by gender, found no significant difference in any of the scores (Table 4).
Hypothesis 2 was tested to look for differences in anxiety, depression, and QOL scores
by age groups (Table 5). Participants aged 18 to ≤60 years had significantly higher anxiety
scores (7.52 ± 3.65) than participants > 60 years (4.86 ± 3.21; p=0.003; Table 5). Participants
aged 18 to ≤60 years had significantly lower QOL domain 4 scores of environmental health
(32.48 ± 5.23) than participants > 60 years (35.94 ± 4.55; p=0.006; Table 5). No significant
differences were found in depression scores, QOL domain 1, QOL domain 2, QOL domain 3, or
global QOL scores based on age groups (Table 5).
Hypothesis 3 was tested to determine differences in anxiety, depression, and QOL scores
by the time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of
metastasis (Table 6). No significant differences were found in anxiety scores, depression scores,
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the four QOL domains, or in the global QOL based on the time elapsed between the initial
diagnosis of uveal melanoma and the diagnosis of metastasis (Table 6).
Hypothesis 4, which was tested to look for differences in anxiety, depression, and QOL
scores by the duration of illness since the diagnosis of metastasis (Table 7), revealed significant
difference in anxiety scores among the three groups (p=0.01; Table 7). Our results showed that
group variances were homogenous. LSD Post hoc analysis revealed that anxiety scores were
significantly higher in the < 1 year group (7.79 ± 3.72) compared to the 1 year to <5 years group
(5.75 ± 3.45; p=0.04), and were significantly higher in the < 1 year group (7.79 ± 3.72)
compared to the ≥ 5 years group (3.80 ± 2.78; p=0.004). There were no statistical significance in
anxiety scores between the 1 year to <5 years group and the ≥ 5 years group (p=0.12).
Moreover, our results showed difference in QOL domain 1 scores for physical health
among the three groups (p=0.05; Table 7). The Least Significant Difference (LSD) Post hoc
analysis revealed that QOL domain 1 scores were significantly higher in the < 1 year group
(29.11 ± 4.03) compared to the 1 year to <5 years group (25.81 ± 5.85; p=0.03). There were no
statistical significance in QOL domain 1 scores between the < 1 year group and the ≥ 5 years
group (p=0.99) or between the 1 year to <5 years group and the ≥ 5 years group (p=0.08). No
significant differences were found in depression scores, QOL domain 2, QOL domain 3, QOL
domain 4, or global QOL based on the duration of illness since metastasis (Table 7).
Discussion
As a referral practice for patients with MUM, we were in a unique position to assess the
levels of anxiety, depression, and quality of life among patients with MUM aged 18 years and
older and determine how many of them had at least borderline anxiety (scores ≥8), at least
borderline depression (scores ≥8), and a decrease in global QOL (scores <7). In our sample there
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were unequal demographic distribution of gender (more female), age range (more older than 60
years), race (more White), ethnicity (more not Hispanic or Latino), highest level of education
completed (more with college education or above), employment status (more non-employed),
marital status (more married), parental status (more parents of children), and being a parent of a
child < 18 years (more without a child less than 18 years). Also, there were unequal distribution
of clinical characteristics of the time elapsed between the initial diagnosis of uveal melanoma
and metastasis (more with 1 year to <5 years), and the duration of illness since metastasis (more
with 1 year to <5 years). This unequal distribution may have influenced results although it likely
reflected the actual demographic and clinical characteristics of patients with MUM.
Moreover, we asked participants to identify themselves in one of the following 3 age
groups: 18-34 year group, 35-60 year group, and >60 year group (Appendix C). We had only 2
patients in the 18-34 year group so we combined the 18-34 year group and the 35-60 year group
into the 18-60 year group. It is possible that the results would have been different if the age
groups were broken down based on the four adult generations identified by the Pew Research
Center (2015): Millennials, (ages 20 to 35 in 2016), Generation X (ages 36 to 51 in 2016),
Boomers (ages 52 to 70 in 2016), and the Silent generation (ages 71 to 88 in 2016).
Similar to previous studies assessing psychosocial disturbances in patients diagnosed
with cancer (Die, 2012; Mitchell et al., 2011; Schuermeyer et al., 2016), approximately one third
of participants had clinically significant anxiety and decreased global QOL. This supports the
concept that the diagnosis of MUM impairs the holistic well-being of patients beyond their
physical examination and clinical presentation.
Also, we hypothesized that there would be a difference in anxiety, depression, and QOL
scores in patients with MUM by gender. Our results showed that gender was not a differentiating
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factor for anxiety scores, depression scores, global QOL scores, or the four QOL domain scores.
These results are different than those of other studies which have indicated that females had
higher anxiety and psychiatric disturbances than males (Kessler et al., 1994; McLean et al.,
2011). However, it may be that the sample size in our study did not yield sufficient power to
completely address these endpoints.
Moreover, we hypothesized that there would be a difference in anxiety, depression, and
QOL scores in patients with MUM by age groups. Our results showed that participants aged 18
to ≤60 years had significantly higher anxiety scores than participants > 60 years. This is in
parallel with Weiss et al. (2015) study which noted that anxiety decreased with increasing age.
Also, participants aged 18 to ≤60 years had significantly lower QOL domain 3 scores of social
relationships than participants > 60 years. The increased anxiety and impaired social
relationships among younger patients with MUM may be due to the diagnosis of MUM
potentiated by the socio-economics constraints that face people aged 18 to ≤60 years such as
financial, marriage, and career-oriented pressures. Likewise, in examining how quality of life in
Ireland varied by age group and social class, using central statistics office data available for
2013, the Economic and Social Research Institute (2016) found that the rate of multiple quality
of life problems was 1.8 times higher in younger adults than in older adults. No significant
differences were found in depression scores, QOL domain 1, QOL domain 2, QOL domain 3,
and global QOL based on age groups. Albeit statistically insignificant differences in these QOL
domains and global QOL scores between age cohorts, the mean scores were higher in
participants > 60 years.
Furthermore, we hypothesized that there would be a difference in anxiety, depression,
and QOL scores in patients with MUM by the time elapsed between the initial diagnosis of uveal
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melanoma and the diagnosis of metastasis. Our results showed no significant differences in
anxiety scores, depression scores, the four QOL domains, and in the global QOL based on the
time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of metastasis.
This may be, that for the most part, patients diagnosed with MUM do not exhibit debilitating
symptoms after the initial treatment of uveal melanoma. Chabert, Velikay-Parel & Zehetmayer
(2004) noted that patients with uveal cancer appeared relatively well and displayed fewer signs
of decline. However, it may be that the unequally sized groups by the time elapsed between the
initial diagnosis of uveal melanoma and the diagnosis of metastasis in our study did not yield
enough power to completely address these endpoints.
In addition, we hypothesized that there would be a difference in anxiety, depression, and
QOL scores by the duration of illness since the diagnosis of metastasis. Participants with < 1
year since the diagnosis of metastasis had significantly higher anxiety scores and higher QOL
domain 1 scores for physical health. No significant differences were found in depression scores,
QOL domain 2, QOL domain 3, QOL domain 4, and in the global QOL based on the duration of
illness since metastasis. The level of anxiety is increased among patients with MUM with < 1
year since the diagnosis of metastasis but the QOL of their physical health is not markedly
affected. During the first year of the diagnosis of metastasis, these patients are in good physical
health yet going through a disturbing experience.
Overall, up to 30% of participants had at least borderline anxiety and a decreased global
QOL while up to 10% had at least borderline depression. These findings have never been
identified in this population although they are clinically significant to justify the need and
importance for integrating psycho-social practices in the care of patients with MUM.
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Study Limitations
The first limitation of this study was the sample size. Generalization of the findings may
be limited as the participants in our study were all part of one institution located in the MidAtlantic region. The results of the level of anxiety, depression, and QOL may be unique to
patients with MUM of this institution. Another limitation was that the sample size of each
category by gender, age groups, was not equally distributed, which could influence the results
and conclusion. In addition, the research may have produced different results if other variables
were also measured such as financial strain, the distance and mode of transport from residence to
the institution, and other forms of deprivation.
Implications and Recommendations for Practice, Policy, and Research
The results of our current study have implications in clinical practice algorithms of
patients with MUM as they reveal a significant level of anxiety, level of depression, and
decreased QOL among these patients. The psychosocial oncology framework by Turnbull et al.
(2012) can be used to present our findings to the multidisciplinary oncology team and have the
team discuss and collectively develop processes to raise awareness among clinicians and patients
about the findings. The team is encouraged to reflect on the current assessment and determine
how the findings can influence a new standard of care regarding a biopsychosocial assessment of
patients with MUM and a development of a plan that links patients and caregivers with necessary
psychosocial services.
The first step will be for healthcare providers to correctly identify patients who are
experiencing anxiety, depression, and decreased quality of life. While patients aged 18-60 have
a higher overall anxiety score, both age ranges remain at risk and should be screened. Gender
and time elapsed between the initial diagnosis of uveal melanoma and the diagnosis of metastasis
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are not differentiating factors for anxiety scores, depression scores, global QOL scores, or the
four QOL domain scores. Time since diagnosis of metastatic malignancy however is associated
and thus our plan will initially be rolled out to identify patients who are within 1 year of their
diagnosis of MUM. To identify these patients more reliably, we will target their first
hospitalization for liver-directed therapy. We recommend training healthcare providers on how
to utilize the HADS and WHOQOL-BREF questionnaire and document anxiety score,
depression score, and QOL scores upon this encounter and then quarterly.
Based on the assessment and diagnosis, the second step will be for the clinician to set and
document measurable and achievable short- and long-term goals specific to every patient with
MUM that might include getting out of the house for a walk at least thirty minutes per day,
eating small but frequent nutritious meals, managing pain and nausea through adequate
medications, consulting a psychiatrist/social worker/case management, recommending music
relaxation, and referring to relaxation techniques for health (American Nurses Association
[ANA], 2018; National Center for Complementary and Integrative Health, 2017).
The third step will be for the clinician to follow the care plan established through the
continuum of care during hospitalization and outpatient (ANA, 2018). Patient identified to have
increased physiological needs and/or socio-psychological distress should be called 2 to 3 days
after hospital discharge by a member of the clinical staff preferably who was on the discharge
team. Throughout the continuum of care, the patient’s status and the effectiveness of the care
plan must be evaluated and modified as needed putting forward holistic and patient-focused care
in an attempt to improve the quality of life of these patients (ANA, 2018).
Further research should address anxiety, depression, and QOL with a larger population
sample of patients diagnosed with MUM, and possibly extend research to other patients
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diagnosed with other types of cancer. Also, we recommend a study looking at the Millennials
(ages 22 to 37 in 2018), Generation X (ages 38 to 53 in 2018), Boomers (ages 54 to 72 in 2018),
and the Silent generation (ages 73 to 90 in 2018). A comparison between strategies used in
different institutions to address anxiety, depression, and QOL may assist clinicians to learn from
each other in order to improve the QOL of patients with MUM through the continuum of care.
Conclusions
In an attempt to improve the quality of life of patients with metastatic uveal melanoma, it
is essential to examine bio-psycho-social-spiritual needs of these patients in daily clinical
practice. The findings of this study offer important contributions by showing the significant level
of anxiety, level of depression, and decreased QOL in patients with MUM using the HADS and
the WHOQOL-BREF questionnaire. It also explored differences by gender, age range, time
elapsed between the initial diagnosis of uveal melanoma and metastasis, and duration of illness
since metastasis. Participants aged 18 to ≤60 years had significantly higher anxiety scores and
lower QOL domain 4 scores of environmental health. Participants with < 1 year since the
diagnosis of metastasis had significantly higher anxiety scores and higher QOL domain 1 scores
for physical health. Gender and time elapsed between the initial diagnosis of uveal melanoma
and metastasis were not differentiating factors for anxiety scores, depression scores, global QOL
scores, or the four QOL domain scores.
The findings of our study also guide stakeholders involved in the care of patients with
MUM to integrate a translational strategic plan addressing bio-psycho-social-spiritual needs in
light of patient-centered care approach to improve the quality of life of these patients. The
psychosocial oncology framework by Turnbull et al. (2012) provided a useful model for this
study.
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Table 1. Variables Affecting Psychosocial Health of Patients with MUM
Variable

Theoretical Definition

Operational Definition

Dependent Variable
Level of anxiety (interval)

Degree of fear, nervousness, Actual anxiety score 0-21
uneasiness, and nerveracking as measured by
scores on the HADS

Level of depression (interval) Degree of ongoing feeling

Actual depression score 0-21

of sadness and loss of
interest as measured by
scores on the HADS
Quality of life (interval)

General well-being of

There is no total score of

individuals in terms of

WHOQOL-BREF. Scores

health and happiness as

are reported by domains and

measured by scores on the

the two global questions are

WHOQOL-BREF.

reported separately. Lower
score scores denote lower
QOL while higher scores
denote higher QOL.
1. Domaine 1 = Physical
health: (6-Q3) + (6-Q4) +
Q10 + Q15 + Q16 + Q17 +
Q18 (Raw score 7-35)
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Operational Definition
2. Domaine 2 =
Psychological health: Q5 +
Q6 + Q7 + Q11 + Q19 + (6Q26) (Raw score 6-30)
3. Domaine 3 = Social
relationships: Q20 + Q21 +
Q22 (Raw score 3-15)
4. Domaine 4 =
Environmental health: Q8 +
Q9 + Q12 + Q13 + Q14 +
Q23 + Q24 + Q25 (Raw
score 8-40)
5. Global QOL/General
health: Q1 + Q2 (Raw score
2-10)

Independent Variable
Age range (nominal)

Gender
(nominal/dichotomous)

Category of years a person

1. Age 18 to ≤60 years

has lived

2. Age > 60 years

Biological determination of

1. Male

sex

2. Female
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Variable

Theoretical Definition

The time elapsed between the Years/months lapsed from
initial diagnosis of uveal
melanoma and the diagnosis the diagnosis of uveal
of metastasis (Categorical)
melanoma to the diagnosis
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Operational Definition
1. <5 years
2. ≥ 5 years

of metastasis
The duration of illness since
the diagnosis of metastasis
(Categorical)

Years/months elapsed since

1. <1 year

diagnosed with MUM as

2. 1 year to <5 years

reported by patient

3. ≥ 5 years

Biological and physical

Race:

characteristics shared by a

1. Black or African

group of individuals as

American

identified by patient

2. White

Demographic Variable
Race (nominal)

3. Prefer Not to Disclose
Ethnicity (nominal)

Cultural traits shared by a

Ethnicity:

group of individuals as

1. Hispanic or Latino

identified by patient

2. Not Hispanic or Latino
3. Other

Marital status (nominal)

Current relationship

1. Married
2. Non-Married

Parental status (Nominal)

Identification of whether or

0= Parent without a child

not a person is a parent

1= Parent with a child
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Variable

Theoretical Definition

Being a parent of a child < 18 Personal identifying of
years (Nominal)
being a parent of a child

Level of education
(Categorical)

Employment status
(Categorical)
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Operational Definition
Age group of child
0. No child (<18 years)

younger than 18 years

1. Child (0- <18 years)

Highest level of schooling

1= High School or less

completed

2= College or above

Status of current

1= Employed

employment

2= Non- Employed
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Table 2. A Descriptive Analysis for Demographic and Clinical Characteristics of the Sample
Variables

Participants

Anxiety score≥8

n (%)

n (%)

Depression
score ≥8

Global QOL
score <7

n (%)

n (%)

65 (100)

20 (30.8)

9 (13.8)

21 (32.3)

Male

28 (43.1)

7 (10.8)

1 (1.5)

7 (10.8)

Female

37 (56.9)

12 (18.5)

8 (12.3)

14 (21.5)

18 to ≤60 years

29 (44.6)

13 (20)

4 (6.2)

12 (18.5)

>60 years

36 (55.4)

7 (10.8)

5 (7.7)

9 (13.8)

White

64 (98.5)

20 (30.8)

9 (13.8)

21 (32.3)

African
American

1 (1.5)

50 (76.9)

16 (24.6)

7 (10.8)

18 (27.7)

11 (16.9)

4 (6.2)

1 (1.5)

3 (4.6)

High school or
less

14 (21.5)

4 (6.2)

4 (6.2)

3 (4.6)

College or
above

51 (78.5)

16 (24.6)

5 (7.7)

18 (27.7)

28 (43.1)

12 (18.5)

6 (9.2)

11 (16.9)

Gender

Age groups

Race*

Ethnicity
Hispanic or
Latino
Not Hispanic
or Latino
Other

2 (3.1)

Education

Employment
status
Employed
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Variables

Non-Employed

Participants

Anxiety score≥8

n (%)

n (%)

37 (56.9)
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Depression
score ≥8

Global QOL
score <7

n (%)

n (%)

8 (12.3)

3 (4.6)

10 (15.4)

Marital status
Married

52 (80)

14 (21.5)

5 (7.7)

16 (24.6)

Non- married

13 (20)

6 (9.2)

4 (6.2)

5 (7.7)

Parental status
No children

8 (12.3)

2 (3.1)

1 (1.5)

2 (3.1)

Yes children

54 (83.1)

16 (24.6)

7 (10.8)

17 (26.1)

No child (< 18
years)

48 (73.8)

12 (18.5)

7 (10.8)

13 (20)

Child (0- < 18
years)

8 (12.3)

4 (6.2)

1 (1.5)

4 (6.2)

2 (3.1)

1 (1.5)

2 (3.1)

Being a parent of
a child <18 years

The time elapsed
between the
initial diagnosis
of uveal
melanoma and
the diagnosis of
metastasis
<1 year

7 (10.8)

1 year to <5
years

40 (61.5)

13 (20)

5 (7.7)

14 (21.5)

<5 years

47 (72.3)

15 (23.1)

6 (9.2)

16 (24.6)

≥ 5 years

18 (27.7)

5 (7.7)

3 (4.6)

5 (7.7)

The duration of
illness since the
diagnosis of
metastasis
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Variables

Participants

Anxiety score≥8

n (%)

n (%)

42
Depression
score ≥8

Global QOL
score <7

n (%)

n (%)

<1 year

19 (29.2)

9 (13.8)

3 (4.6)

6 (9.2)

1 year to <5
years

36 (55.4)

9 (13.8)

5 (7.7)

12 (18.5)

10 (15)

1 (1.5)

1 (1.5)

3 (4.6)

≥ 5 years

* Due to low variability, race is not used in bivariate or inferential statistical analysis
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Table 3. Anxiety, Depression, and QOL Scores in Patients with MUM
Participants

Minimum

Maximum

n=65, 100%
Mean (SD)
Anxiety (score)

6.05 (3.64)

0

16

Depression (score)

3.48 (3.27)

0

13

QOL Domain 1

27.28 (5.38)

15

35

QOL Domain 2

23.52 (4.59)

11

30

QOL Domain 3

11.71 (2.35)

5

15

QOL Domain 4

34.40 (5.13)

22

40

Global QOL

7.22 (1.57)

3

10
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Table 4. Differences in Anxiety, Depression, and QOL Scores by Gender
Gender

Analysis

Male

Female

n=28, 43.1%

n=37, 56.9%

Mean (SD)

Mean (SD)

P value

t-test

Anxiety (score)

5.68 (3.62)

6.32 (3.68)

-0.71

0.48

Depression (score)

2.71 (2.39)

4.05 (3.73)

-1.76

0.84

QOL Domain 1

27.89 (4.98)

26.81 (5.68)

0.80

0.43

QOL Domain 2

24.46 (4.36)

22.81 (4.70)

1.45

0.15

QOL Domain 3

12.07 (2.16)

11.43 (2.48)

1.09

0.28

QOL Domain 4

34.14 (4.56)

34.59 (5.57)

-0.35

0.73

7.36 (1.25)

7.11 (1.78)

0.63

0.53

Global QOL
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Table 5. Differences in Anxiety, Depression, and QOL Scores by Age Group
Age range in years
Age 18 to ≤60 years
n=29, 44.6%

Age >60 years
n=36, 55.4%

Analysis

P value

t-test

Anxiety (score)

Mean (SD)
7.52 (3.65)

Mean (SD)
4.86 (3.21)

3.12

0.003

Depression (score)

3.52 (3.31)

3.44 (3.28)

0.09

0.93

QOL Domain 1

26.31 (5.55)

28.06 (5.18)

-1.31

0.20

QOL Domain 2

22.83 (5.16)

24.08 (4.07)

-1.10

0.28

QOL Domain 3

11.21 (2.88)

12.11 (1.75)

-1.48

0.15

QOL Domain 4

32.48 (5.23)

35.94 (4.55)

-2.85

0.006

Global QOL

7.03 (1.57)

7.36 (1.57)

-0.83

0.41
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Table 6. Differences in Anxiety, Depression, and QOL Scores by the Time Elapsed between
Initial Diagnosis of Uveal Melanoma and Metastasis
Time elapsed between

Time elapsed between

Analysis

initial diagnosis of uveal

initial diagnosis of uveal

t-test

melanoma and

melanoma and

metastasis

metastasis

< 5 years

≥ 5 years

n=47, 72.3%

n=18, 27.7%

Mean (SD)

Mean (SD)

P value

Anxiety (score)

6.45 (3.74)

5.00 (3.22)

1.45

0.15

Depression (score)

3.91 (3.35)

2.33 (2.83)

1.77

0.08

QOL Domain 1

27.34 (5.35)

27.11 (5.58)

0.15

0.88

QOL Domain 2

23.04 (4.46)

24.78 (4.83)

-1.37

0.18

QOL Domain 3

11.57 (2.50)

12.06 (1.92)

-0.74

0.47

QOL Domain 4

33.94 (5.19)

35.61 (4.89)

-1.18

0.24

Global QOL

7.09 (1.49)

7.56 (1.76)

-1.09

0.28
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Table 7. Differences in Anxiety, Depression, and QOL Scores by the Duration of Illness since
Metastasis
Duration of

Duration of

Duration of

Analysis

illness since

illness since

illness since

ANOVA

metastasis

metastasis

metastasis

< 1 year

1 year to <5 years

> 5 years

n=19, 29.2%

n=36, 55.4%

n=10, 15.4%

Mean (SD)

Mean (SD)

Mean (SD)

P value

Anxiety (score)

7.79 (3.72)

5.75 (3.45)

3.80 (2.78)

4.88

0.01

Depression (score)

3.05 (2.97)

4.08 (3.43)

2.10 (2.96)

1.70

0.19

QOL Domain 1

29.11 (4.03)

25.81 (5.85)

29.10 (4.56)

3.23

0.05

QOL Domain 2

23.68 (4.76)

22.72 (4.60)

26.10 (3.51)

2.23

0.12

QOL Domain 3

12.11 (2.69)

11.19 (2.19)

12.80 (1.87)

2.18

0.11

QOL Domain 4

34.42 (5.17)

33.56 (5.33)

37.40 (3.20)

2.22

0.12

7.26 (1.49)

7.08 (1.66)

7.60 (1.43)

0.50

0.65

Global QOL
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Causal Model of Variables Affecting Psychosocial Health of Patients with MUM
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Consort Diagram of Study Participants
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Appendix H
Data Definition Code for Anxiety, Depression, and Quality of Life in Patients with Metastatic
Uveal Melanoma
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